Royalty Pharma plc OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax
Royalty Pharma plc (RPRX) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax of $52.18 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax · last filed 2020-11-12
- Royalty Pharma plc oci, debt securities, available-for-sale, gain (loss), before adjustment, after tax for the quarter ending 2020-09-30 was $3.80M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax 9 month |
|---|---|---|---|
| 2020-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $52.18M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $48.38M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |